PRAX
Live chart
What they do
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies.
For information only · Important disclosures
Grades vs sector
No sector grades for PRAX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Held by 1 of 5 live models: New Highs Growth.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.81 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-9.50 vs trailing $-12.95. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 87.7 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $0 | $-303.3M | $-249.1M |
| 2024 | $8.6M | $-182.8M | $-131.8M |
| 2023 | $2.4M | $-123.3M | $-111.2M |
| 2022 | $0 | $-214.0M | $-185.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -3.69 | -2.87 | +22.2% |
| 2026-05-07 | -3.68 | -3.20 | +13.0% |
| 2026-02-19 | -3.13 | -3.50 | -12.0% |
| 2025-11-05 | -3.49 | -3.36 | +3.7% |
| 2025-08-04 | -3.36 | -3.31 | +1.4% |
| 2025-05-02 | -3.21 | -3.29 | -2.5% |
| 2025-02-28 | -2.82 | -2.94 | -4.3% |
| 2024-11-06 | -1.95 | -2.75 | -40.9% |
Stats refreshed 2026-10-21 18:16:06 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026